WO2005115441A3 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone - Google Patents

Compositions and methods for enhanced mucosal delivery of parathyroid hormone Download PDF

Info

Publication number
WO2005115441A3
WO2005115441A3 PCT/US2005/016530 US2005016530W WO2005115441A3 WO 2005115441 A3 WO2005115441 A3 WO 2005115441A3 US 2005016530 W US2005016530 W US 2005016530W WO 2005115441 A3 WO2005115441 A3 WO 2005115441A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucosal delivery
methods
parathyroid hormone
compositions
enhanced mucosal
Prior art date
Application number
PCT/US2005/016530
Other languages
French (fr)
Other versions
WO2005115441A2 (en
Inventor
Steven C Quay
Henry R Costantino
Mary S Kleppe
Ching-Yuan Li
Original Assignee
Nastech Pharm Co
Steven C Quay
Henry R Costantino
Mary S Kleppe
Ching-Yuan Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co, Steven C Quay, Henry R Costantino, Mary S Kleppe, Ching-Yuan Li filed Critical Nastech Pharm Co
Priority to CA002567056A priority Critical patent/CA2567056A1/en
Priority to JP2007513324A priority patent/JP2007537274A/en
Priority to MXPA06012980A priority patent/MXPA06012980A/en
Priority to EP05780065A priority patent/EP1750756A2/en
Priority to AU2005247369A priority patent/AU2005247369A1/en
Publication of WO2005115441A2 publication Critical patent/WO2005115441A2/en
Publication of WO2005115441A3 publication Critical patent/WO2005115441A3/en
Priority to NO20065673A priority patent/NO20065673L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Abstract

Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human.
PCT/US2005/016530 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone WO2005115441A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002567056A CA2567056A1 (en) 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
JP2007513324A JP2007537274A (en) 2004-05-10 2005-05-10 Compositions and methods for enhancing mucosal delivery of parathyroid hormone
MXPA06012980A MXPA06012980A (en) 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone.
EP05780065A EP1750756A2 (en) 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
AU2005247369A AU2005247369A1 (en) 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
NO20065673A NO20065673L (en) 2005-05-10 2006-12-08 Compositions and Methods for Improved Mucosal Delivery of Parathyroid Hormone.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57011304P 2004-05-10 2004-05-10
US60/570,113 2004-05-10

Publications (2)

Publication Number Publication Date
WO2005115441A2 WO2005115441A2 (en) 2005-12-08
WO2005115441A3 true WO2005115441A3 (en) 2006-03-16

Family

ID=35207584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016530 WO2005115441A2 (en) 2004-05-10 2005-05-10 Compositions and methods for enhanced mucosal delivery of parathyroid hormone

Country Status (9)

Country Link
US (6) US7244709B2 (en)
EP (1) EP1750756A2 (en)
JP (1) JP2007537274A (en)
CN (1) CN101151048A (en)
AU (1) AU2005247369A1 (en)
CA (1) CA2567056A1 (en)
MX (1) MXPA06012980A (en)
RU (1) RU2006143544A (en)
WO (1) WO2005115441A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
JP2004535432A (en) * 2001-06-22 2004-11-25 ベントレー ファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
EP1750756A2 (en) * 2004-05-10 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CA2610626A1 (en) * 2005-06-02 2006-12-07 Alza Corporation Method for terminal sterilization of transdermal delivery devices
KR100700869B1 (en) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 The stabilized parathyroid hormone composition comprising parathyroid hormone buffer and stabilizing agent
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
EP1919939A2 (en) * 2005-07-27 2008-05-14 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery
EP1931374A2 (en) * 2005-10-06 2008-06-18 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
CN101355959B (en) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2007106597A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia
US8226949B2 (en) * 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) * 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) * 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP2049149B1 (en) * 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
WO2008016729A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
CA2663074A1 (en) * 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
AU2007322334B2 (en) * 2006-10-03 2011-12-22 Ipsen Pharma S.A.S. Method of drug delivery for bone anabolic protein
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008065144A2 (en) * 2006-11-29 2008-06-05 Novartis Ag Galenic formulations of organic compounds
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
EP2152245B1 (en) * 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008145730A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP2164466A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CA2714506C (en) * 2008-02-08 2016-06-07 Qps Llc Composition for sustained release delivery of proteins or peptides
US9260502B2 (en) * 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
PL2910570T3 (en) 2008-03-18 2017-06-30 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2586032T3 (en) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
AU2009269117A1 (en) * 2008-07-11 2010-01-14 Map Pharmaceuticals, Inc. Containers for aerosol drug delivery
ES2616231T3 (en) * 2008-08-21 2017-06-12 Immunogenics Llc Formulation for oral protein administration
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN102316850A (en) * 2009-02-11 2012-01-11 海格兰德公司 A composition for buccal absorption of nicotine for the purpose of smoking cessation
US20100256060A1 (en) * 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
CN103893746A (en) * 2009-09-09 2014-07-02 旭化成制药株式会社 Pth-containing therapeutic/prophylactic agent for osteoporosis
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
BR112012013725A2 (en) 2009-12-07 2017-01-10 Univ Michigan Tech black bear parathyroid hormone and methods of using the black bear parathyroid hormone.
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
EP2857028A4 (en) * 2012-05-25 2016-04-06 Lion Corp Agent containing ascorbic acid derivative, and use for said agent
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6946182B2 (en) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ Therapeutic Vitamin D Conjugate
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
IL301616A (en) 2016-03-01 2023-05-01 Ascendis Pharma Bone Diseases As Pth prodrugs
RS64440B1 (en) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
RU2766959C2 (en) 2016-09-29 2022-03-16 Асцендис Фарма Боун Дизизис А/С Pth compounds with low peak-to-minimum ratios
CN110087674B (en) 2016-12-16 2023-01-03 诺和诺德股份有限公司 Pharmaceutical composition containing insulin
KR102322802B1 (en) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic form of RAD1901-2HCL
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
CN110996988A (en) * 2017-09-22 2020-04-10 旭化成制药株式会社 Liquid pharmaceutical composition containing teriparatide with excellent stability
US10195147B1 (en) 2017-09-22 2019-02-05 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN111163827A (en) * 2017-11-27 2020-05-15 丽年控股有限公司 Carburetor system
AU2019270464A1 (en) * 2018-05-18 2020-11-19 Ascendis Pharma Bone Diseases A/S Starting dose of PTH conjugates
CA3102509A1 (en) * 2018-06-10 2019-12-19 Zim Laboratories Limited Oral mucosal delivery systems comprising monophasic concentrate of teriparatide
CN112423844A (en) 2018-07-04 2021-02-26 雷迪厄斯制药公司 Polymorphic forms of RAD1901-2HCL
CN109133356B (en) * 2018-09-12 2021-09-14 浙江海洋大学 Method for removing algae by using filter feeders
AU2020221491A1 (en) * 2019-02-11 2021-08-05 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
WO2021183474A1 (en) * 2020-03-09 2021-09-16 University Of Houston System Inflammatory bowel disease stem cells, agents which target ibd stem cells, and uses related thereto
MX2023002285A (en) * 2020-08-26 2023-05-16 Cila Therapeutic Inc Inhalable therapeutic agents.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US20030039654A1 (en) * 2000-04-27 2003-02-27 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3272873D1 (en) * 1981-06-04 1986-10-02 Pharmasol Corp Pressurized container with dispensing pump
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
EP0559751B1 (en) 1990-11-26 1997-03-26 RECKER, Robert R. Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
JPH05238929A (en) 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd Long term-sustainable pharmaceutical preparation for metabolic osteopathy treatment
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
ATE211655T1 (en) 1993-09-22 2002-01-15 Hisamitsu Pharmaceutical Co IONTOPHORESIS MATRIX
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
ATE219374T1 (en) 1996-02-01 2002-07-15 Chugai Pharmaceutical Co Ltd MEDICATIONS FOR THE TREATMENT OR PREVENTION OF THROMBOCYTOPENIA
JPH10130171A (en) 1996-09-04 1998-05-19 Dot:Kk Pharmaceutical composition for oral administration
AP9901686A0 (en) * 1997-05-14 1999-12-31 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs.
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
EA200000672A1 (en) * 1997-12-18 2000-12-25 Эли Лилли Энд Компани CRYSTAL TERIPARATIDE
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
AR033639A1 (en) * 1998-08-19 2004-01-07 Lilly Co Eli USE OF PARTIROID HORMONES TO PREPARE MEDICINES TO REDUCE THE RISK OF VERTEBRAL OR NON-VERTEBRAL OSEAS FRACTURES IN HUMAN BEINGS WITH RISK OF SUFFERING OR WHO HAVE OSTEOPOROSIS
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
JP2003519169A (en) * 1999-12-30 2003-06-17 インターミューン インコーポレイテッド Gamma-IFN droplet aerosol and method
AU2002306433B2 (en) * 2001-02-02 2004-10-07 Lh Skin Care Llc Skin care product delivery system
WO2003035028A1 (en) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20030185762A1 (en) * 2002-03-22 2003-10-02 Cowan Siu Man L. Highly aqueous liquid carrier formulations
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
JP4949838B2 (en) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス New GLP-1 derivative
US6941871B2 (en) * 2003-11-05 2005-09-13 Sidney Wayne Mauldin Faceted expansion relief perforating device
KR20070010115A (en) 2003-11-13 2007-01-22 알자 코포레이션 Composition and apparatus for transdermal delivery
US7192919B2 (en) * 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
EP1750756A2 (en) 2004-05-10 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052306A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US20030039654A1 (en) * 2000-04-27 2003-02-27 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20040077540A1 (en) * 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CODRONS VALERIE ET AL: "Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 92, no. 5, May 2003 (2003-05-01), pages 938 - 950, XP002354437, ISSN: 0022-3549 *
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS. 2004, vol. 21, no. 1, 2004, pages 21 - 66, ISSN: 0743-4863 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 January 2004 (2004-01-01), NEWMAN STEPHEN P ET AL: "Drug delivery to the nasal cavity: in vitro and in vivo assessment.", XP002354439, Database accession no. NLM15099184 *

Also Published As

Publication number Publication date
US7244709B2 (en) 2007-07-17
EP1750756A2 (en) 2007-02-14
CN101151048A (en) 2008-03-26
US20100184688A1 (en) 2010-07-22
US20070167364A1 (en) 2007-07-19
JP2007537274A (en) 2007-12-20
WO2005115441A2 (en) 2005-12-08
AU2005247369A1 (en) 2005-12-08
US20070154401A1 (en) 2007-07-05
US20050276843A1 (en) 2005-12-15
CA2567056A1 (en) 2005-12-08
US20070154400A1 (en) 2007-07-05
MXPA06012980A (en) 2007-06-12
RU2006143544A (en) 2008-06-20
US7435720B2 (en) 2008-10-14
US20070244049A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2005115441A3 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2005080433A3 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
BRPI0509991A (en) aerosol delivery apparatus, methods and compositions for pressure-assisted breathing systems
IL179197A0 (en) Apparatus and method for transdermal delivery of parathyroid hormone agents
HK1096014A1 (en) Transdermal hormone delivery system: compositions and methods
HK1101554A1 (en) Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
WO2007059136A3 (en) Rankl antibody-pth/pthrp chimeric molecules
AU2003278766A1 (en) Method and device for the controlled delivery of parathyroid hormone
IL172769A0 (en) Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
EP1729817A4 (en) Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
WO2005117584A3 (en) Improved transmucosal delivery of peptides and proteins
IL159714A (en) Pharmaceutical composition for oral delivery comprising a fragment of parathyroid hormone and 5-cnac
WO2006102990A3 (en) Tablet containing steroid hormones
HUP0400120A3 (en) Pharmaceutical composition for orally administering parathyroid hormone and calcitonin
GB2446341A (en) Method and system for transdermal drug delivery
GB0304636D0 (en) Pharmaceutical composition for nasal delivery
NO20026055L (en) Pharmaceutical Components Including Human Parathyroid Hormone And Pharmaceutical Compositions For Nasal Administration Containing The Components
GB0228305D0 (en) Therapeutic composition for respiratory delivery
NO20065673L (en) Compositions and Methods for Improved Mucosal Delivery of Parathyroid Hormone.
TW200509960A (en) Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2007005320A3 (en) Methods of delivering corticotroph-derived glycoprotein hormone
WO2007005995A3 (en) Compositions for buccal delivery of human growth hormone
WO2007112682A8 (en) Recombinant human parathyroid hormone-related proteins and uses thereof
SI1471890T1 (en) Pharmaceutical dosage form for mucosal delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007513324

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2567056

Country of ref document: CA

Ref document number: PA/a/2006/012980

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 6674/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 551875

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005247369

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006143544

Country of ref document: RU

Ref document number: 2005780065

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580023137.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005247369

Country of ref document: AU

Date of ref document: 20050510

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005247369

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005780065

Country of ref document: EP